Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 5 art units • 6 examiners • 0 of 8 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
BIOASTER’s portfolio is in Biotechnology & Pharmaceuticals and has 8 pending office actions. The matters involve 6 distinct examiners and 5 distinct art units, showing that prosecution is spread across several examination channels. That distribution creates a coordination issue: counsel must maintain matter-specific analysis while identifying recurring technical or claim-drafting themes across the portfolio.
KIM, YOUNG J is the busiest examiner, with 2 pending matters. The remaining pending activity is distributed among other examiners and art units, so KIM’s matters should receive focused attention without treating them as representative of the entire record. A practical review should align deadlines, compare response positions, and preserve consistency where related biotechnology and pharmaceutical claims raise similar issues.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (50%) |
| §103 only | 1 (12%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 2 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YOUNG J | 2 | 64.8% | +18.2% |
| MYERS, CARLA J | 2 | 49.5% | +46.0% |
| ZHANG, WAYNE | 1 | 59.3% | +43.3% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.5% |
| SWITZER, JULIET CAROLINE | 1 | 42.4% | +54.0% |
| GAO, ASHLEY HARTMAN | 1 | 56.5% | +38.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18580232 | USE OF TORQUE TENO VIRUS (TTV) AS A MARKER TO DETERMINE THE RISK OF COMPLICATIONS IN A PATIENT ADMITTED TO A HEALTHCARE FACILITY | KIM, YOUNG J | 14d |
| 18014801 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT | MYERS, CARLA J | — |
| 18014885 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT | SWITZER, JULIET CAROLINE | — |
| 18014814 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT | MYERS, CARLA J | — |
| 18014878 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT | KIM, YOUNG J | — |
| 17294327 | METHODS AND REAGENTS FOR MULTIPLEX BINDING EXPERIMENTS | GAO, ASHLEY HARTMAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18580232 | USE OF TORQUE TENO VIRUS (TTV) AS A MARKER TO DETERMINE THE RISK OF COMPLICATIONS IN A PATIENT ADMITTED TO A HEALTHCARE FACILITY | KIM, YOUNG J | 14d |
| 18031972 | METHOD FOR CLASSIFYING AN INPUT IMAGE REPRESENTING A PARTICLE IN A SAMPLE | ZHANG, WAYNE | 27d |
| 18014934 | METHOD FOR DETERMINING THE RISK OF COMPLICATION IN A PATIENT | KINSEY WHITE, NICOLE ERIN | — |
| 18014801 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT | MYERS, CARLA J | — |
| 18014885 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT | SWITZER, JULIET CAROLINE | — |
| 18014814 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT | MYERS, CARLA J | — |
| 18014878 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT | KIM, YOUNG J | — |
| 17294327 | METHODS AND REAGENTS FOR MULTIPLEX BINDING EXPERIMENTS | GAO, ASHLEY HARTMAN | — |
| Art Unit | Apps |
|---|---|
| 1682 | 3 |
| 1681 | 2 |
| 2672 | 1 |
| 1672 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18580232 | USE OF TORQUE TENO VIRUS (TTV) AS A MARKER TO DETERMINE THE RISK OF COMPLICATIONS IN A PATIENT ADMITTED TO A HEALTHCARE FACILITY | KIM, YOUNG J | 1681 | §101§103§112 | Final Rejection | 14d | Pending | Jan 18, 2024 |
| 18031972 | METHOD FOR CLASSIFYING AN INPUT IMAGE REPRESENTING A PARTICLE IN A SAMPLE | ZHANG, WAYNE | 2672 | §103 | Final Rejection | 27d | Pending | Apr 14, 2023 |
| 18014934 | METHOD FOR DETERMINING THE RISK OF COMPLICATION IN A PATIENT | KINSEY WHITE, NICOLE ERIN | 1672 | §103§112DP | Final Rejection | — | Pending | Jan 06, 2023 |
| 18014801 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT | MYERS, CARLA J | 1682 | §101§102§112Other | Non-Final OA | — | Pending | Jan 06, 2023 |
| 18014885 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT | SWITZER, JULIET CAROLINE | 1682 | §101§103§112Other | Final Rejection | — | Pending | Jan 06, 2023 |
| 18014814 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT | MYERS, CARLA J | 1682 | §101§102§112Other | Non-Final OA | — | Pending | Jan 06, 2023 |
| 18014878 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-RELATED INFECTION IN A PATIENT | KIM, YOUNG J | 1681 | §103§112 | Final Rejection | — | Pending | Jan 06, 2023 |
| 17294327 | METHODS AND REAGENTS FOR MULTIPLEX BINDING EXPERIMENTS | GAO, ASHLEY HARTMAN | 1678 | §103§112 | Final Rejection | — | Pending | May 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIOASTER has 8 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Young J Kim has the most, with 2 of BIOASTER's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
